Insmed
INSM
288 hedge funds and large institutions have $4.07B invested in Insmed in 2024 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 97 increasing their positions, 97 reducing their positions, and 29 closing their positions.
62% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 29
6% more funds holding
Funds holding: 271 → 288 (+17)
0% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 97
4.76% less ownership
Funds ownership: 105.75% → 100.99% (-4.8%)
13% less capital invested
Capital invested by funds: $4.69B → $4.07B (-$621M)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
33% less call options, than puts
Call options by funds: $67.7M | Put options by funds: $101M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$118M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$45.4M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$37.5M |
| 4 |
IHAM
Integral Health Asset Management
New York
|
+$26.6M |
| 5 |
ClearBridge Investments
New York
|
+$26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$67.1M |
| 2 |
Morgan Stanley
New York
|
-$59.6M |
| 3 |
Holocene Advisors
New York
|
-$50M |
| 4 |
Millennium Management
New York
|
-$37.2M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$30.5M |
INSM Hedge Fund Activity: Q1 2024 in Review
288 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q1 2024, worth a combined $4.07B — down 13% from $4.69B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new INSM positions and 29 closed out — a net gain of 18 holders — while 97 added to existing stakes and 97 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $118M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $67.1M.
- 288 institutional investors held Insmed (INSM) as of Q1 2024, up from 271 in Q4 2023.
- Funds reported $4.07B of Insmed stock for Q1 2024, down 13% quarter-over-quarter.
- 47 funds opened new Insmed positions in Q1 2024 and 29 closed out, a net change of +18 holders.
- The largest Insmed buyer in Q1 2024 was Fidelity Investments, an estimated $118M added.
- The largest Insmed seller in Q1 2024 was T. Rowe Price Investment Management, an estimated $67.1M sold.
Based on aggregated 13F filings for Q1 2024.